Clinical Research

GeNeuro targets retrovirus protein in MS

Recent positive data from a Phase 2b trial of patients with multiple sclerosis illustrates the role of pathogenic HERV-W protein in the genesis of the disease. The protein was neutralised by an antibody therapy developed by GeNeuro SA, the first time this has been shown in a clinical trial.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Combination IO study in melanoma stopped

A Phase 3 trial in which a combination of Keytruda (pembrolizumab) and the IDO1 inhibitor epacadostat were being studied in patients with metastatic melanoma has been stopped after failing to show a benefit in progression-free survival, according to Incyte Corp and Merck & Co Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Vobarilizumab fails in systemic lupus erythematosus

Vobarilizumab, a protein therapeutic that showed efficacy at Phase 2 in rheumatoid arthritis, has failed to meet the primary endpoint of dose response in a separate Phase 2 study of patients with systemic lupus erythematosus.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

SafeHeal raises €6 million in Series A

SafeHeal SAS, a French company with a medical device to help patients recover from bowel surgery, has received €6 million in Series A financing from investors led by Sofinnova Partners. The funds will support a study that is being run to obtain a CE mark in Europe, and commercial development.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Tecentriq shows PFS benefit in lung cancer

The second arm of a Phase 3 study of the checkpoint inhibitor Tecentriq (atezolizumab) in patients with advanced lung cancer has shown a progression free survival (PFS) benefit when combined with chemotherapy, according to the developer Roche.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Alzheimer’s drug has effect at higher dose

An experimental drug for Alzheimer’s disease that has failed in successive trials to show efficacy, demonstrated for the first time that it can reduce amyloid beta plaques in the brain at a higher dose. Gantenerumab achieved an effect at dosing of up to 1200 mg.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

MYSTIC trial results to be later than expected

AstraZeneca Plc said that final data from its Phase 3 MYSTIC trial which is testing a combination immunotherapy for non-small cell lung cancer, are now expected in the second half of the year, rather than in the first half.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Novartis invests in digital trials

Novartis has expanded an alliance with Science 37 Inc of the US to launch up to 10 clinical trials over the next three years that will be conducted at a participant’s home or a physician’s officer rather than at a formal clinical trial site. Science 37 is a mobile technology and clinical trial company.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Verona reports positive data from CF trial

Verona Pharma Plc has reported positive top-line data from a Phase 2a trial of its inhaled drug for patients with cystic fibrosis, a rare inherited disease that causes impaired lung function and premature death. The data showed an improvement in lung function that was statistically significant.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Novartis, Pear in digital drug alliance

Novartis has announced a collaboration with Pear Therapeutics Inc to develop digital therapeutics for patients with schizophrenia and multiple sclerosis using mobile and desktop software. The new products would deliver clinically-proven treatments such as cognitive behavioural therapy.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Syndicate content